Abstract: Adverse drug reactions (ADRs) are considered as an important cause of morbidity and mortality. The hypersensitivity reactions are immune-mediated ADRs, which are dose-independent, unpredictable and have been associated with several HLA alleles. The present review aimed to describe HLA alleles that have been associated with different ADRs in populations worldwide, the recommendations of regulatory agencies and pharmacoeconomic information and databases for the study of HLA alleles in pharmacogenetics. A systematic search was performed in June 2016 of articles relevant to this issue in indexed journals and in scientific databases (PubMed and PharmGKB). The information of 95 association studies found was summarized. Several HLA alleles and haplotypes have been associated with ADRs induced mainly by carbamazepine, allopurinol, abacavir and nevirapine, among other drugs. Years with the highest numbers of publications were 2013 and 2014. The majority of the reports have been performed on Asians and Caucasians, and carbamazepine was the most studied ADR drug inducer. Two HLA alleles' databases are described, as well as the recommendations of the U.S. Food and Drug Administration, the European Medicine Agency and the Clinical Pharmacogenetics Implementation Consortium. Pharmacoeconomic studies on this issue are also mentioned. The strongest associations remain for HLA-B*58:01, HLA-B*57:01, HLA-B*15:02 and HLA-A*31:01 but only in certain populations; therefore, studies on different ethnic groups would be useful.
Introduction
Immunologic-mediated adverse drug reactions (ADRs) are included in type B ADRs which are not related to the dose and that are uncommon and unpredictable in that they are not related with the pharmacodynamics of the drug and present high mortality [1] . There is evidence that susceptibility to at least some Type B ADR is found under strong genetic influence [2] , and identifying genetic risk factors for this type of ADRs could significantly decrease healthcare costs and improve the process of drug development [3] .
The drug-activated immune response is known to be mediated by T cells when the drug molecule binds to T-cell receptors (TCR). The majority of existing drug molecules have a comparable size of one to three amino acids, which is much smaller than the peptide ligands of human leukocyte antigen (HLA) class I (8-12 mers) and class II (9-25 mers) molecules [4] . Accordingly, the following five hypotheses have been proposed in order to explain T-cell recognition of a drug antigen presented by a HLA molecule: (i) the hapten/pro-hapten theory, (ii) the p.i. concept, (iii) the "altered repertoire" model, (iv) the "altered T-cell receptor repertoire" model and (v) the danger hypothesis [4] [5] [6] (Figure 1) .
Briefly, the first hypothesis postulates that the drug or its immunogenic metabolite binds by covalent bonds to an endogenous peptide and to the HLA molecule, which particularly explains the hypersensitivity to beta-lactam antibiotics. The p.i. ("pharmacological interaction with the immune receptor") concept considers a non-covalent and reversible binding of the molecule directly to the HLA molecule and/or the TCR, which could be the case for carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) and the HLA-B*15:02 allele. The "altered repertoire" model proposes that a drug can non-covalently bind to the self-peptide repertoire and alter the conformation of this peptide repertoire presented to HLA and TCR protein, inducing cutaneous adverse drug reactions (cADRs); in this case, the drug may not directly bind to HLA, and this hypothesis elucidates in part the association of HLA-B*57:01 and abacavir-induced cADRs. The "altered TCR repertoire" model suggests that the drug interacts first with the TCR, which undergoes a conformational change that, in turn, allows binding with an HLA molecule to induce the immune response. Finally, the danger hypothesis explains that immune responses are caused by endogenous cellular alarm signals (i.e. CD40L, TNF-α, IL-1β and IFN-α) from distressed or injured cells, which could occur after the processing of the drug as antigen [4] [5] [6] .
As mentioned previously, several HLA alleles have been associated with different induced ADRs. The majority of these are related with cADRs, which comprise mild ailments such as maculopapular exanthema (MPE) and severe syndromes such as the SJS, toxic epidermal necrolysis (TEN) and the drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) [6, 7] . Furthermore, there are reports that also support the implication of variations in immune genes with drug-induced liver injury (DILI) [8] [9] [10] [11] [12] , drug-induced proteinuria [13] and agranulocytosis [14] .
The most common descriptions of associations of HLA alleles with ADRs were reported for HLA-B*15:02 and CBZ-induced SJS [15] , HLA-B*58:01 and allopurinolinduced SJS or DIHS [16] and HLA-B*57:01 with a hypersensitivity reaction to abacavir [17] . Over time, several association studies have been performed in different populations, and some of these have described that the associated HLA allele is drug-specific and that ethnicity matters [18] . Moreover, guideline recommendations by regulatory agencies have been published in order to prevent different cADRs by means of HLA genotyping prior to drug prescription, and databases are now available to supply information on HLA alleles associated with ADR throughout the world. Therefore, in the light of these advances in HLA alleles in ADRs the present review aimed to describe HLA alleles that have been associated with several ADRs in worldwide populations, the recommendations of regulatory agencies, pharmacoeconomic information and databases for the study on HLA alleles in pharmacogenetics.
Methods
We performed a systematic search in June 2016 of relevant articles for this issue in indexed journals and scientific databases (PubMed and PharmGKB). Search words included "HLA and adverse drug reactions". Association studies in which at least one HLA allele was related with the risk of ADR occurrences were included in the corresponding section. Articles were selected according to their relevance on the subject. The whole body of information was analyzed and summarized.
HLA alleles associated with adverse drug reactions
Ninety-five articles reporting that HLA alleles have been associated with ADRs were selected, and the main information of the association study was summarized in Table 1 for CBZ-induced cADRs, Table 2 for HLA alleles related to other antiepileptic drugs-induced cADRs, Table 3 for allopurinol, abacavir and nevirapine studies with HLA and ADRs and Table 4 (Table 3) .
There are several reports of other HLA alleles associated with other different drugs-induced ADRs, for instance, amoxicillin-clavulanate, antituberculosis drugs, asparaginase, aspirin, clozapine, cold medications, co-trimaxole, dapsone and penicillins, among others. The type of ADRs included in these studies comprises hypersensitivity, cADR, drug-induced liver injury, proteinuria, agranulocytosis and other specific reactions, such as aspirin-exacerbated respiratory disease and cold medicine-related SJS/TEN with severe ocular-surface complications. In some cases, the studies have only been performed in one population, and the information remains not sufficiently strong to be considered in clinical recommendations ( Table 4) .
The studies included comprise years of publication from 1993 to 2016 with at least one study reporting an association between HLA alleles and ADRs published per year. The highest number of reports was published in 2013 and 2014 (13 per year), which is 6 years after the U.S. Food and Drug Administration (FDA) recommendation on genetic screening for patients of Asian ancestry prior to the initiation of CBZ therapy [112] and when the number of studies in this subject increased. The majority of the investigations have studied CBZ-induced cADRs (29%), followed by allopurinol-and lamotrigine-induced cADRs (13% and 7%, respectively). Few studies have been performed for abacavir-and phenytoin-induced hypersensitivity (6% for each) and for ADRs induced by amoxicillin-clavulanate, nevirapine and oxcarbazepine (4% for each). Fifty-five percent of the studies have included Asian patients in whom there is a notably higher incidence of cADRs than in Caucasians [113] ; however, an important percentage of these reports was also performed in individuals of Caucasian ancestry (42%); Africans have only been included in one study and individuals from America in three. [26] ADR, adverse drug reaction; cADR, cutaneous adverse drug reaction; CI, confidence interval; DRESS, drug reactions with eosinophilia and systemic symptoms; HLA, human leukocyte antigen; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; ND, not determined; n +/tot, number of subjects positive for the HLA allele associated/total of subjects included in the association study; OR, odds ratio; SCAR, severe cutaneous adverse drug reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
Databases with HLA alleles and adverse drug reactions
As can be observed in Tables 1-4 , several class I and II HLA alleles have been associated with ADRs in different populations. The HLA allele associated in a certain ethnic group is largely influenced by the frequency of the specific allele among the studied population [18, 114] . In order to facilitate the investigation and associations of HLA alleles and ADRs, two databases have been designed [115, 116] . Both of these permit easy and rapid access to relevant information about a specific drug, ADR or HLA allele related with ADR pharmacogenomics.
One of these belongs to the Allele Frequency Net Database (http://www.allelefrequencies.net), a free, centralized resource that contains information on the allele, the haplotype and the genotype frequencies of several immune genes, including HLA alleles, in different populations [117] . This website was released in 2003 [118] , and since then, the database has grown significantly in terms of the number of populations covered and the number of users and citations [115] . Therefore, to assist HLA and pharmacogenetic studies, this database contains collated data sets from the literature, with information that not only facilitates metaanalyses but that also enables users to examine the quality of published studies by comparing the frequencies of HLA alleles reported in healthy volunteers' cohorts with those ADR, adverse drug reaction; cADR, cutaneous adverse drug reaction; CI, confidence interval; DRESS, drug reactions with eosinophilia and systemic symptoms; HLA, human leukocyte antigen; MPE, maculopapular exanthema; ND, not determined; n + /tot, number of subjects positive for the HLA allele associated/total of subjects included in the association study; OR, odds ratio; SCAR, severe cutaneous adverse drug reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
of worldwide populations. This resource only includes case-control studies with statistical evidence provided for the association and in which high-resolution HLA genotyping was performed. From each report, information about ethnicity, the drug of interest and the proportion of cases and controls carrying the HLA allele implicated in ADRs is extracted and summarized in the database [115] . The second of these is denominated the HLADR database (http://pgx.fudan.edu.cn/hladr/). This is an in-house database that manually collected the information of 1786 records after an extensive search and review of the literature and curation of reports of HLA alleles associated with ADRs. The information compiled from each report contains the following: drugs, ADRs, HLA alleles, the ethnic and geographic origins of the study subjects, a 2 × 2 contingency table reflecting the association strengths (p-value, odds ratio [OR], sensitivity, specificity, positive-predictive values and negative-predictive values) and FDA drug-labeling changes resulting from the drug-HLA associations. The association strengths across different studies were incomparable because different statistical methods were applied in the original reports; consequently, the designers of this database performed the Fisher's exact test and the Haldane's modification to recalculate the p-value and the OR for each association study, respectively. In addition, this resource standardized the names of ADRs and HLA alleles based on reference databases such as PharmGKB and international ImMunoGeneTics (IMGT) project/HLA [116] . ADR, adverse drug reaction; AHS, abacavir hypersensitivity; cADR, cutaneous adverse drug reaction; CI, confidence interval; HLA, human leukocyte antigen; MPE, maculopapular exanthema; ND, not determined; NS, not specified; n + /tot, number of subjects positive for the HLA allele associated/total of subjects included in the association study; OR, odds ratio; SCAR, severe cutaneous adverse drug reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis. 
International medicine agencies recommendations on HLA alleles and drug prescriptions
International medicine agencies as the FDA in the U.S. and the European medicine agency (EMA) have made recommendations based on evidence published about HLA alleles associated with ADRs in drugs such as CBZ, allopurinol, abacavir and phenytoin, among others. These data have been added to the specific drug-label information in order to improve the safety of the drug and to inform physicians about the usefulness of performing HLA genotyping prior to prescribing the drug [112, 119] . In addition, the clinical pharmacogenetics implementation consortium (CPIC) has published guidelines for the dosing of abacavir, allopurinol, CBZ and phenytoin considering the patient's HLA genotype [120] [121] [122] [123] [124] [125] [126] [127] . Recommendations from the three previously mentioned international medicine agencies are summarized in Table 5 . For abacavir, the international medicine agencies and the CPIC highly recommend HLA genotyping in all patients with HIV of any ethnicity prior the prescription of this drug and avoiding the administration of abacavir in patients who are carriers of the HLA-B*57:01 allele. In contrast, for allopurinol there is no well-established recommendation for routine HLA testing, although EMA and CPIC consider that the prescription of allopurinol should be evaluated carefully if it is known that the patient is an HLA-B*58:01 carrier. In the case of CBZ, genetic testing for HLA is recommended in patients with Asian ancestry or, specifically, for Han Chinese and Thai population, but the use of this antiepileptic is contraindicated in any patient positive for the HLA-B*15:02 allele regardless of the patient's ancestry. In addition, the agencies recommend that the use of CBZ in patients carrying HLA-A*31:01, especially of Caucasian or Japanese origin, should be considered if the benefits are thought to exceed the risks. Additionally, the recommendation for antiepileptic drug prescription is to avoid phenytoin and, in some cases, oxcarbazepine, eslicarbazepine acetate and lamotrigine in patients positive for HLA-B*15:02.
Pharmacoeconomic perspective of HLA genotyping prior to drug prescription
Among the benefits of the use of pharmacogenomics in clinical practice are those of guiding the initial drug [111]
ADR, adverse drug reaction; AERD, aspirin-exacerbated respiratory disease; ATLI, antitubercular drug-induced liver injuries; cADR, cutaneous adverse drug reaction; CI, confidence interval; CM-SJS/TEN with SOC, cold medicine-related SJS/TEN with severe ocular-surface complications; DIH, drug-induced hepatotoxicity; DIHR, dapsone-induced hypersensitivity reactions; HLA, human leukocyte antigen; DILI, drug-induced liver injury; DRESS, drug reactions with eosinophilia and systemic symptoms; HSS, hypersensitivity syndrome; MPE, maculopapular exanthema; ND, not determined; NS, not specified; n + /tot, number of subjects positive for the HLA allele associated/total of subjects included in the association study; OR, odds ratio; SJS, StevensJohnson syndrome; SLE, systemic lupus erythematosus; TEN, toxic epidermal necrolysis. regimen, individualizing the regimen, increasing efficacy and avoiding ADRs [131] ; thus, the implementation of pharmacogenomics in routine practice can improve different drug treatments [132] . Pharmacogenetic testing is also of relevance for the economic resources of the patient or the public health system. Several studies have demonstrated that HLA testing prior to various drug prescriptions is costeffective but that this also depends on the population to which it will be applied. For instance, HLA-B*15:02 genotyping prior to CBZ prescription is cost-effective for Singaporean Chinese, Malays and Thai patients [133, 134] but not for Singaporean Indians [133] . For Europeans, a study reports that testing for HLA-A*31:01 represents a cost-effective use prior to initiation of CBZ therapy [135] . Contrariwise, testing for HLA-B*58:01 did not represent a benefit in allopurinol therapy in Singaporean patients, in contrast with the profit observed in Thai and Korean populations [71, 136] . HLA-B*57:01 screening prior to abacavir was found to be cost-effective for patients from Spain and Germany [137, 138] . However, a systematic review found that there is cost-effectiveness in the use of pharmacogenetic biomarkers to avoid ADRs in common drug therapies [139] .
On the other hand, several investigations have been performed in order to develop assays that reduce the cost of HLA screening, i.e. nested allele-specific PCR and PCR-RFLP for HLA-A*31:01 detection [140, 141] , flow cytometry pre-screening [142] , real-time PCR [143] for HLA-B*57:01 and the flow cytometry test for HLA-B*58:01 [144] . Furthermore, the search for single-nucleotide polymorphisms in linkage disequilibrium with specific HLA alleles could diminish the cost of HLA genotyping and make it more available for different populations [145, 146] .
However, there are some limitations for HLA genotyping in cases of rare ADRs that should be taken into account. In general, the incidence of ADRs associated with HLA alleles is low; for instance, allopurinol hypersensitivity has been reported in 0.1% [147] , and it represents a problem in association studies. This explains the small sample size observed in the majority of studies, which limits the study power for detecting significant associations [148] ; however, meta-analyses can help solve this problem, especially in populations that are widely studied. In addition, investigations employing a scarce number of patients could lead to many associated HLA alleles, in which further studies are required in order to confirm their use as pharmacogenetic biomarkers. This situation could impact the cost-effectiveness of HLA typing prior to drug prescription in uncommon ADRs [149] .
In sum, several HLA alleles have been associated with ADRs to common drugs; however, the strongest associations remain for HLA-B*58:01, HLA-B*57:01, HLA-B*15:02 and HLA-A*31:01, but only in certain populations. In addition, the majority of the studies have been performed in Asians and Caucasians, and there is a lack of reports on other populations. This situation renders it difficult for international medicine agencies to offer global recommendations on HLA genotyping prior to drug prescription or for their including more populations in their warnings. Moreover, it might be possible that more HLA alleles are associated with ADRs in other, not yet studied ethnic groups; therefore, pharmacogenomic investigations on this issue should not be pushed aside. The existence of HLA allele databases that facilitate these studies and the reports that assure the cost-effectiveness of HLA screening could ease pharmacogenomic research of ADRs focused on HLA alleles.
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